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http://dx.doi.org/10.1016/j.ccr.2013.11.002SUMMARYRhabdomyosarcoma is a soft-tissue sarcoma with molecular and cellular features of developing skeletal
muscle. Rhabdomyosarcoma has two major histologic subtypes, embryonal and alveolar, each with distinct
clinical, molecular, and genetic features. Genomic analysis shows that embryonal tumors have more struc-
tural and copy number variations than alveolar tumors. Mutations in the RAS/NF1 pathway are significantly
associated with intermediate- and high-risk embryonal rhabdomyosarcomas (ERMS). In contrast, alveolar
rhabdomyosarcomas (ARMS) have fewer genetic lesions overall and no known recurrently mutated cancer
consensus genes. To identify therapeutics for ERMS, we developed and characterized orthotopic xenografts
of tumors that were sequenced in our study. High-throughput screening of primary cultures derived from
those xenografts identified oxidative stress as a pathway of therapeutic relevance for ERMS.Significance
Our data show that the genetic landscapes of embryonal rhabdomyosarcomas (ERMS) and alveolar rhabdomyosarcomas
(ARMS) are distinct. ARMS have fewer mutations overall and no recurrent cancer consensus gene mutations. In contrast,
ERMS have a high rate of recurrent mutations in the RAS pathway. We selected six ERMS patient tumors to generate ortho-
topic xenografts and optimized a culture system for high-throughput screening of primary xenograft tumor cells to test their
drug sensitivity. None of the molecularly targeted therapeutics for the RAS pathway had any significant activity, but the
oxidative stress pathway is a promising cellular target for primary and recurrent ERMS. These data suggest that cell biology
studies may be combined with genomic analyses to identify druggable pathways for rhabdomyosarcoma.
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Rhabdomyosarcoma is themost common soft-tissue sarcoma of
childhood and adolescence (Gurney et al., 1999). Using contem-
porary multimodal therapies, more than 75% of patients with
localized disease are cured (Crist et al., 2001). However, despite
the availability of new agents and the intensification of therapy,
patients with recurrent or metastatic rhabdomyosarcoma experi-
ence 5 year survival rates of only 17% or 30%, respectively
(Pappo et al., 1999). Rhabdomyosarcoma can be divided into
two broad histopathologic subtypes: embryonal rhabdomyosar-
coma (ERMS) that accounts for about 60% of all rhabdomyosar-
comas and alveolar rhabdomyosarcoma (ARMS) that accounts
for about 25% of all rhabdomyosarcomas (Newton et al., 1988).
The remaining cases are classified as mixed, unspecified, or un-
differentiated sarcomas (Rudzinski et al., 2013). Patients with
ERMS have a relatively good prognosis, and the tumors are char-
acterized by the loss of heterozygosity at the 11p15 locus (Ognja-
novic et al., 2009; Scrable et al., 1989). In contrast, patients with
ARMShavean inferior clinical outcome,and their tumorsareoften
characterized by a translocation between the FOXO1 gene on
chromosome 13q14 and either PAX3 on chromosome 2q35 or
PAX7 on chromosome 1p36 (Barr, 1997; Raney et al., 2001).
Current treatment protocols for rhabdomyosarcoma are de-
signed to deliver risk-based therapy (low, intermediate, or high)
based exclusively on the clinical and pathologic features at the
time of initial presentation (Malempati and Hawkins, 2012). How-
ever, the outcome for an individual child, particularly a child with
intermediate-risk disease features, is still difficult to predict. This
indicates that clinical and pathologic features alone are impre-
cise. Biologic signatures within clinical subgroups might offer a
more reliable method for predicting outcome and assigning
risk-based or targeted therapies (Davicioni et al., 2010).
In this study, we characterized the genomic, epigenomic,
molecular, and cellular features of rhabdomyosarcoma and inte-
grated those data with drug sensitivity data to identify druggable
pathways for this devastating pediatric cancer.
RESULTS
Sequencing of Rhabdomyosarcoma
We performed whole-genome sequencing (WGS) analysis on 16
rhabdomyosarcoma tumors from 13 patients and on matched
normal tissue. Nine of the patients had ERMS and four patients
had ARMS. The distribution of patient age, sex, race, primary
site, and stage reflected the clinical heterogeneity of the disease.
We also sequenced three recurrent tumor samples from two
ERMS patients (Table S1 available online).
Using a paired-end sequencing approach, we generated
4,529 Gb of sequence data for the samples described; 4,260
Gb (94%) were successfully mapped to the reference genome
(Table S2). The average genome coverage was 423, and the
average exon coverage was 373; 99% of SNPs detected across
all 29 genomes showed concordance with their corresponding
SNP array genotype calls at the same genomic positions (Table
S2). We also performed RNA sequencing on 15 of the 16 tumors
used for WGS (Table S2).
All somatic alterations including sequence mutations and
structural variations (SVs) were experimentally validated byCacustom-capture technology and Illumina sequencing. We identi-
fied 22,123 validated somatic sequence mutations and 1,275
validated SVs across the 16 tumors (Table S2). These included
409 nonsilent tier-1 mutations in genes; 1,980 tier-2 mutations
in regulatory regions or evolutionarily conserved regions of the
genome; and 19,202 tier-3 mutations in nonrepetitive regions
of the genome that are not part of tier 1 or tier 2 (Table S2).
The average number of sequence mutations was 1,382.7 per
case (range, 290–3,135), with 25.6 mutations per case (range,
5–65) resulting in amino acid changes (Table S2). The average
number of validated SVs was 79.7 per case (range, 2–299).
The estimated mean background mutation rate was 1.06 3
106 per base (range, 2.35 3 107–2.42 3 106). We also iden-
tified and validated 22 SVs that are predicted to produce an
in-frame fusion protein in our discovery cohort (Table S2). RNA
sequencing revealed that eight of those predicted in-frame
fusions were expressed in the tumors (Table S2). Five of eight
of the expressed in-frame fusion transcripts were the result of
the PAX3/7-FOXO1 translocations in ARMS tumors. The other
three transcripts were FGFR1-WHSC1L1 in SJRHB001, NSD1-
ZNF346 in SJRHB011, and a 2.7 kb intragenic deletion in
COL4A2 in SJRHB002 (Table S2 and Figures S1A–S1C). These
results show that despite an overall high number of SVs in
ERMS cases, very few resulted in functional fusion genes.
CopyNumber Variations and SVs in Rhabdomyosarcoma
Previous array comparative genomic hybridization (aCGH)
studies have shown that ARMS tumors tend to have fewer
copy number variants (CNVs) than do ERMS tumors (Williamson
et al., 2010). We found a trend toward increased SVs and CNVs
in ERMS, comparedwith those in ARMS, in our discovery cohort,
but SV data did not achieve statistical significance because of
the small number of ARMS tumors (Figures 1A and 1B). SVs
and CNVs can be caused by the gradual, progressive accumula-
tion of chromosomal and regional lesions during each round of
cell division, or they may be caused by a single acute event
such as chromothripsis (Stephens et al., 2011). We found no
evidence of chromothripsis in the 16 rhabdomyosarcoma tumors
in our discovery cohort (data not shown; see Supplemental
Experimental Procedures for details). Instead, the multilevel
CNVs in genomic regions with multiple complex SVs suggested
accumulation of sequential chromosomal lesions rather than a
single acute event (Figure 1C).
The background mutation rate (BMR) and overall number of
single-nucleotide variants (SNVs) was significantly higher in
ERMS tumors than in ARMS tumors (Figure 1C). A mutation
spectrum estimated using validated SNVs throughout the whole
genome (Figures S1D and S1E) indicated that ERMS tumors had
significantly more G/T SNVs than did ARMS tumors (26.7%
versus 19.9%; p = 0.031) and that the combined proportion of
G/T transversions in rhabdomyosarcoma (24.9%) was higher
than that found in T cell acute lymphoblastic leukemia (T-ALL)
and medulloblastoma (MB) (T-ALL + MB, 17.8%; p = 0.0003)
(Robinson et al., 2012; Zhang et al., 2012) but lower than that
found in lung cancer (32.7%; p = 0.00014) (Cancer GenomeAtlas
Network, 2012). Oxidative stress stimulated p38 mitogen-acti-
vated protein kinases (MAPKs), and consistent with this obser-
vation, MAPK12 expression was significantly higher in ERMS
compared with ARMS (false discovery rate [FDR] = 0.02;ncer Cell 24, 710–724, December 9, 2013 ª2013 Elsevier Inc. 711
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Figure 1. Genomic Landscape of ERMS Is Distinct from that of ARMS
(A) Boxplots of validated BMRs, number of nonsilent SNVs, total SVs, and number of total CNVs in the ERMS and ARMS tumors in the discovery cohort.
(B) Representative CIRCOS plots of validated mutations and chromosomal lesions in two ERMS and two ARMS tumors in the discovery cohort. LOH (orange),
gain (red), and losses (blue) are shown. Intrachromosomal translocations (green lines) and interchromosomal translocations (purple lines) are indicated.
Sequence mutations in Refseq genes included silent SNVs (green), nonsense and missense SNVs (brown), splice-site and UTR mutations (dark blue), and
insertion/deletion mutations (red).
(legend continued on next page)
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Genomic Analysis of Rhabdomyosarcoma2.1-fold change). In addition, MAP2K6 was overexpressed in
ERMS (FDR = 0.0003; 3.3-fold change). Taken together, these
data are consistent with the hypothesis that oxidative stress
contributes to the SNVs identified in rhabdomyosarcomas.
Intratumoral Heterogeneity and Clonal Evolution in
ERMS Recurrence
As a first step to analyze intratumor heterogeneity in the discov-
ery cohort, the tumor purity (i.e., ratio of tumor cells to all cells)
was estimated from the WGS data. For each tumor, regions of
the genome that had copy number alterations (CNAs) and corre-
sponding changes in their loss of heterozygosity (LOH) were sur-
veyed to identify the maximum proportional representation of a
somatic lesion in the tumor. We were able to estimate the tumor
purity in 15 of the 16 tumors (ranged from 67% to 98% in our dis-
covery cohort; Figure S2C). Next, we analyzed intratumor het-
erogeneity using the purity-adjusted mutant allele frequency
(MAF) derived from deep sequencing of all SNVs by capture
enrichment and Illumina sequencing. We excluded SJRHB013
from this analysis because of low tumor purity. The majority of
tumors (13/15) had tumor-purity-adjusted MAF peaks corre-
sponding to 0.5, indicating that the tumor purity estimates from
CNAs and LOH analysis are accurate (Figure S2). Using somatic
SNVs found in the diploid chromosomal regions, we found that
therewas amajorMAF peak around 0.25 for three of the samples
(SJRHB001, SJRHB009, and SJRHB004). These data suggest
that there are relatively few mutations in the founding clone,
and a subclone representing50% of the tumor has the majority
of SNVs. Overall, 10 of the 15 tumors had evidence of significant
intratumor heterogeneity and two of the tumors (SJRHB004 and
SJRHB011_D) had more than two subclones (Figure S2).
To characterize the clonal evolution (Nowell, 1976) of ERMS
after treatment, we analyzed tumors from two patients who
had diagnostic and recurrent tumors sequenced along with their
matching normal germline genomes. For SJRHB011, a recurrent
tumor sample (SJRHB011_D) was compared with the diag-
nostic tumor isolated 15 months earlier (SJRHB011_E) (Figures
2A–2C). For SJRHB012, tumor samples from two recurrent
sites (SJRHB012_R and SJRHB012_S) that were collected at
the same time were compared with the primary tumor
(SJRHB012_D) isolated 14 months earlier (Figures 2D–2F). In
both cases, the patients received chemotherapy and radiation
before surgical resection of the recurrent tumors. We designed
a single capture chip for each patient that included all tier 1–4
predicted mutations in primary and recurrent tumors from their
corresponding WGS analysis. Deep sequencing of the captured
DNA allowed us to calculate the MAFs for all SNVs across each
of these five tumor samples. This approach allowed us to distin-
guish de novo SNVs that arose in the recurrent samples frommu-
tations that were present at low frequencies in the primary tumor
and that were missed due to intratumor heterogeneity and/or
limited coverage of the WGS.
In SJRHB011, there were 3,524 SNVs with sufficient coverage
for our analysis, and we focused on 841 heterozygous mutations(C) Representative plot of sequence reads on chromosome 3 (Chr3) for the matc
change are indicated by arrows. For clarity, some of the gene names have been
gene disrupting SVs have been removed.
See also Tables S1 and S2 and Figure S1.
Cain diploid regions of the genome without LOH. There were four
major clusters (A–D) (Figure 3A). Cluster A SNVs were found in
cells that were present in the major clone in both primary
(MAF = 0.49) and recurrent (MAF = 0.53) tumors. Cluster B
SNVs were found in cells in the major clone of the recurrent tu-
mor but not the primary tumor. Cluster C SNVs were present in
the recurrent tumor in a subclone, and cluster D SNVs were pre-
sent in the majority of cells in the primary tumor but were lost
in the recurrent sample after chemotherapy (Figure 3A). At diag-
nosis, there was a major clone (clone 2) and a minor clone
(clone 1) contributing 97% and 3% to the tumor, respectively
(Figure 3B). After treatment, the major clone (clone 2) was elim-
inated, and some of the cells from the minor clone (clone 1)
acquired additional SNVs (clone 3) to seed the recurrent tumor.
This recurrent tumor then further evolved into two major clones
(clone 3 and clone 4), contributing 66% and 34% to the tumor,
respectively (Figure 3B).
A similar analysis was performed for SJRHB012 using 1,049
validated SNVs in diploid regions of the genome without LOH.
For this tumor, there were six clusters of SNVs (Figure 3C). Clus-
ter A SNVs were present in all three tumor samples (diagnostic
and two recurrent sites) from this patient (Figures 3C and 3D).
Cluster B SNVs were present in virtually all tumor cells at both
recurrent sites but absent from the primary tumor (Figure 3D).
These mutations were likely acquired early during progression
before spreading to the secondary sites. An ALK mutation
(P1445H) is one of the mutations in this cluster. Cluster C
SNVs were absent from the diagnostic tumor but were present
at one site of recurrence (pelvis) as the dominant clone and at
the other site (prostate) as a minor clone (Figure 3D). Cluster D
and cluster E SNVs were unique to the pelvic or prostate recur-
rent sites, respectively. Cluster F SNVs were found in the domi-
nant clone in the primary tumor but were lost after treatment
(Figure 3D).
Similarly to SJRHB011, the recurrent tumors in SJRHB012
were derived from the founding minor clone (clone 1) after
acquiring additional mutations, including theALKP1445Hmutation
(clone 3). A fraction of the clone 3 cells acquired additional mu-
tations and became clone 4. Both clones 3 and 4 seeded the
two recurrent tumor sites and continued to evolve (clones 5
and 6). Taken together, these data highlight the complex genetic
changes and clonal evolution that occur in ERMS tumors after
treatment.
SJRHB011, SJRHB 012, and SJRHB 013 Xenografts
To begin to study ALK and other signaling pathways that may be
perturbed in primary and recurrent ERMS, we developed and
characterized six orthotopic xenografts derived from the diag-
nostic and recurrent samples for SJRHB011 and SJRHB012
and from the posttreatment SJRHB013 tumor specimen. Immu-
nohistochemistry (IHC) and transmission electron microscopy
confirmed that the cellular features of the patients’ tumors
were preserved in the xenografts in immunocompromised
mice (Figures 4A and 4B and Figures S3A–S3F). SNP 6.0hed germline (green) and tumor (red) sample. Distinct regions of copy number
removed from the CIRCOS plots. In SJRHB003 and SJRHB004, the labels for
ncer Cell 24, 710–724, December 9, 2013 ª2013 Elsevier Inc. 713
AB
H&E
myogenin
D
E
H&E
myogenin
100 µm
100 µm
100 µm
100 µm
recurrence (pelvis)
SJRHB012
15 months
ifosfamide
doxorubicin
etoposide
radiation
C
diagnostic (neck-lymph node)
SJRHB011
recurrence (infratemporal fossa)
SJRHB011
diagnostic (prostate)
SJRHB012
F
recurrence (prostate)
SJRHB012
doxorubicin
etoposide
radiation
14 months
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
LOC100
128164
LOC644669
ADAMTS18
LO
C
646851 T
N
FR
S
F2
5
CACNA1H
SLC25A47
CYP2B7P1
G
O
LG
A7
B
CNTNAP2
KIAA1024
KIAA1199
AR
HG
EF
4
SLC10A7
ACSM2A
COR
O1C
RP
LP
0P
2
M
S4
A4
A
ACAD
10
ABHD15
MAP3K5
ABCA10
C
8orf48
V
P
S
13
D
KCT
D10
SI
PA
1L
2
ZNF346
ZNF862
PTPR
N
2
MDGA
2
PLAG
L2
CL
EC
2B
TCEB3B
CPPED1
DP
YS
L5
ME
TTL
1
PIK3CA
G
RE
M
2
PSAPL1
LA
M
C
2
KC
NA
6
PDE4D
AP
LN
RP
IW
IL4
NETO2
EXOC7ACCN1
KC
NE
4
HTR1B
HTR1B
PRKCB
FGFR4
CPEB2
CX
CR
1
P
X
E
R
2
ZN
F41
P
LA
G
1
NE
LL2
LR
P1
B
AS
PN
C
D
1E
TBCK
FNIP1
IFT5
7
PH
B2
SLIT3
NSD1
TP53
MME
NFIC
R
M
I1
TJP1
ZIC1
C
LU
BLK
SJRHB011_E
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
ADAMTS18
PCDHGA11
C
20orf114
AR
H
G
EF
11
CACNA1H
SLC25A47
G
O
LG
A7
B
KIAA1024
KIAA1199
AR
HG
EF
4
ZN
F780AC19orf59
TSPAN13
SLC
17A
8COR
O1C
SP
AT
A1
9
AT
G1
6L
1
AD
O
RA
1
C
APN
12
ABCA10
ZNF346
PTPR
N
2
SP
AG
17
ATP8B4
ME
TT
L1
MYO
1H
ZNF451
AR
M
C
4
OR
2M
2
M
UC16
M
UC16
M
UC16
DMXL2
PD
CD
4
LA
M
C
2
C
C
D
C
3
PI
W
IL
4
KC
NC
2
SU
MF
1
NETO2
EXOC7
IL17
RB
ACCN1
AG
BL
5
G
PR
88
HTR1B
HTR1B
PRKCB
PCYT2
FGFR4
P2R
X6
PR
EX2
ZN
F41
NE
LL
2
LR
P1
B
DGKH
S
M
C
5
IG
FN
1
MEPE
AS
PN
C
D
72
SO
X6
IFT5
7
ZPBP
NSD1
EVC2
TP53
MME
R
M
I1
AT
M
DCK
TJP1
JMY
FGA
FGA
SA
G
NTS
SJRHB011_D
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
DKFZp434L192
ADAMTSL3
K
IA
A
03
19
L
LO
H1
2C
R1
HERPUD2
FAM
123B
RN
F1
44
A
PABPC1L
TM
EM
74
S
LC
24A
2
CPAMD8
GABRA2
DU
SP
16
INO
80
D
SEC24ASEC24A
PDLIM5
STXBP5
AM
PD
3
O
R5
1T
1
SP
TB
N1
ATP8A1
SAMD5
ADCY9
ACAC
B
DD
X4
7
SC
N5A
4
P
H
P
N
KI
F2
6B
A2
ML
1
GP
R1
9
U
BE3C
MD
M2
PDE6B
TBX20
BLCAP
FA
N
K1
HE
BP
1
PR
EL
P
R
H
O
C
TYMS
BZW
2
LD
HA
LZTS1
PH
F8
FRS2
BTF3
CPM
GP2
S
H
B
SJRHB012_D
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
C
8o
rf4
4-
SG
K3 LO
C
154872
ADAMTSL3
LO
H1
2C
R1
SLC
22A
10
ZDHHC14
K
IA
A
04
67
H
ER
PU
D
2
ALOX5AP
FA
M
12
3B
AT
XN
7L
2
PABPC
1L
SLCO
2A1
CPAM
D8
DNAH17
CTNND2
TXNDC2
SL
C
18
A1
CT
NN
A3
MANS
C1
N
PB
W
R
1
DNAJC3
DU
SP
16
SORCS2
CARD11
INO
80
D
RE
CQ
L4
ZNF653
O
SBPL3
FER
M
T1
STXBP5
TRIM16
KL
H
L3
8
SE
C1
6B
E
B
U
3L2
PAR
P15
SAMD5
ARMC2
HE
CW
2
WDR81
G
IG
YF1
G
IG
Y
F1
CN
TN
6
N
P
P
H
4
SRRM2
DHRS4
ABCC5
A2M
L1
ABCB5
U
B
E
3C
OR
5T3
R
EN
BP
TBX20
TT
C
28
TT
C1
5
KLHL7
ER
BB
4
OR6S1
HERC1
FA
NK
1
SPG11
USP31
VPS41
R
H
O
C
SYN
J1
JAZF1
TYMS
LD
HA
PLIN4
LZ
TS
1
SMG1
MYL2
MIOS
PF
N4
G
JA
8
CC
NJCC
NJ
C
ST4
ETV
6
TL
R4
LRP6
H
IC
2
AL
K
AL
K
LYZ
SJRHB012_S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
C
8o
rf4
4-
SG
K3
LO
C
15
48
72
ADAMTSL3
LO
H1
2C
R1
ST
AM
BP
L1
ZDHHC14
K
IA
A
04
67
H
ER
PU
D
2
ALOX5AP
FA
M
12
3B
TR
A
P
P
C
9
AT
XN
7L
2
PABPC
1L
SLCO
2A1
DNAH17
CTNND2
TXNDC2
SL
C
18
A1CT
NN
A3
MA
NS
C1
OR
5AP
2
DNAJC3
DU
SP
16
SETD1A
SORCS2
CARD11
INO
80
D
ZN
F653
O
SBPL3
ABLIM2
FER
M
T1
STXBP5
TRIM16
SE
C1
6B
PAR
P15
SAMD5
ARMC2
HE
CW
2SHISA6
ITGA2B
D
C
O
4
K
WDR81
G
IG
YF1
G
IG
Y
F1
O
P
LA
H
CN
TN
6
P
N
H
4
P
SRRM2
DHRS4
ABCC5
A2M
L1
COPS3
U
BE
3C
OR
5T3
R
EN
BP
TBX20
TT
C1
5
KLHL7
ER
BB
4
OR6S1
HERC1
FA
NK
1
SPG11
AFAP1
USP31
VPS41
GMPS
R
H
O
C
S
YN
J1
JAZF1
TYM
S
LD
HA
PLIN4
DGKB
AC
R
C
SMG1
MYL2
P
C
N
T
PPIL2
TR
IB
1
MIOS
G
JA
8
CC
NJCC
NJ
C
ST4
ETV6
TL
R4
TUT
1
LRP6
ST
K3
I
H
2
C
AL
K
AL
K
SJRHB012_R
Figure 2. Recurrent ERMS Acquire New Mutations
(A and B) Section of the diagnostic tumor from patient SJRHB011. (A) Hematoxylin and eosin staining (H&E). (B) Myogenin IHC.
(C) CIRCOS plots of validated sequence mutations and chromosomal lesion in the diagnostic tumor and the recurrent specimen.
(D and E) Section of the diagnostic tumor from patient SJRHB012. (D) H&E. (E) Myogenin IHC.
(legend continued on next page)
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Cancer Cell
Genomic Analysis of Rhabdomyosarcomaanalysis, exome sequencing, RNA-seq, and DNA methylation
analysis confirmed that these xenografts closely recapitulate
the molecular features of their primary tumors (Figures 4C–4F
and Figures S3A–S3F). There was no correlation between acqui-
sition of the ALKP1445H mutation and ALK protein levels in
SJRHB012 (Figures S3F and S3G). To test the sensitivity of these
ERMS xenograft tumor cells to ALK inhibitors and other thera-
peutics, we developed and validated a short-term culture proto-
col that was amenable to high-throughput screening. There was
no relationship between ALK mutation status and sensitivity to
ALK inhibitors for SJRHB012 or the other ERMS xenografts
(SJRHB011 and SJRHB013) (Figure S3H).
Recurrent Mutations in Genes Implicated in Muscle
Development and Homeostasis
It has been proposed that rhabdomyosarcomas may arise from
multipotent mesenchymal progenitor cells, muscle progenitor
cells, or muscle stem cells (satellite cells) (Hettmer and Wagers,
2010). These possibilities are not mutually exclusive, and it is
possible that ERMS and ARMS may have distinct cellular
origins. To explore muscle differentiation pathways in ERMS
and ARMS, we performed network analysis, as described previ-
ously (Hu et al., 2012; Zhang andHorvath, 2005), using published
gene expression data for ERMS and ARMS tumors (Davicioni
et al., 2010; Williamson et al., 2010). The WNT and sonic hedge-
hog (SHH) pathways differed significantly between the two rhab-
domyosarcoma subtypes. To validate and extend those data, we
extended our RNA-seq analysis to 32 tumors, including the 15
samples from the discovery cohort described above. We also
performed DNA methylation analysis using the Illumina 450k
BeadChip on 32 tumors (20 ERMS and 12 ARMS) (Figure S4A
and Table S3). Several genes in the WNT and SHH pathways
were differentially expressed, and a subset of those were differ-
entially methylated (Table S4). We did not identify any recurrent
gene mutations in the SHH pathway in our discovery cohort, but
we did identify b-catenin-activating mutations in the WNT
pathway in SJRHB004 and SJRHB005 (Figure 5A). Tumors
with b-catenin-activating mutations accumulated nuclear b-cat-
enin protein in contrast to those that expressed wild-type b-cat-
enin (Figure 5B). We extended our immunohistochemical
analysis of b-catenin and found that 20% (6/30) of ERMS had
some evidence of nuclear localization and 0% (0/17) of ARMS
had evidence of nuclear b-catenin (Table S1). The nuclear b-cat-
enin expression was heterogeneous, ranging from rare cells to
extensive (3+) staining within the tumor tissue (Table S1).
To estimate the frequency of mutations identified in our dis-
covery cohort, we performed targeted resequencing of all exons
for 139 of those genes with mutations in an additional cohort
comprising 21 ERMS, 13 ARMS, and 3 unspecified tumors
(Table S5). Approximately half of the tumors had no mutations
in any of the 139 genes, so we performed exome sequencing
on a subset (28/36) of the tumors (Table S5). All mutations iden-
tified in this subset were validated using Next-Generation ampli-
con sequencing.(F) CIRCOS plot of validated sequence mutations and chromosomal lesion in the
were collected at recurrence for this patient. CIRCOS plots are presented as in Fig
In SJRHB012_R, the labels for gene-disrupting SVs, noncoding mutations, and s
See also Figure S2.
CaTo determine whether any of themuscle specification or differ-
entiation pathways were mutated in rhabdomyosarcomas, we
analyzed the distribution of mutations in genes that are enriched
in developing muscle compared with other human tissues. We
selected all genes that were enriched by at least 4-fold in one
of the three cell populations—myoblast, myotube, or skeletal
muscle—for a total of 1,295 genes. We identified 130 mutations
across 101 genes from our group of muscle-enriched genes in
the discovery and validation cohorts. Nine of those genes—
ANKRD10, COL4A3, DMD, KLHL4, LTBP1, MIB1, MYOD1,
P2RX6, and SYNE2—were mutated in two independent tumor
samples, and TTN was mutated in three samples (Table S6).
Four genes—CTNNA3, MACF1, MAP3K5, and MEF2A—had
two different mutations in the same patient’s tumor (Table S6).
Overall, 70% (19/27) of the ERMS and 44% (8/18) of the ARMS
had a mutation in at least one of the 1,295 muscle-enriched
genes in our analysis, but we detected no statistically significant
enrichment in mutations in the muscle development/differentia-
tion pathways. Taken together, these data on the mutational
landscapes of ERMS and ARMS do not provide any additional
evidence about cellular origins for these tumors.
The most common chromosomal alteration in rhabdomyosar-
coma is the gain of chromosome 8 in ERMS tumors (Williamson
et al., 2010). We analyzed the gene expression in ERMS tumors
with chromosome 8 gains in comparison with those without
chromosome 8 gains. Overall, there was a slight increase in
expression of genes on chromosome 8 in the ERMS tumors
with chromosomal gains (Figure S4B). However, none of the indi-
vidual genes on chromosome 8 were significantly upregulated in
the tumors with chromosome 8 gain. There were seven genes
on other chromosomes with significantly different expression
(FDR % 0.05) in the ERMS tumors with chromosome 8 gains
comparedwith thosewithout chromosome8 gains. Among those
genes, MICU1, MCU, MAMDC2, and ISL1 were altered byR2-
fold (Figure S4C). MCU is a calcium uniporter in mitochondria
and MICU1 is an EF-hand protein that is the key regulator of
MCU. BothMCU andMICU1 are downregulated in ERMS tumors
with chromosome 8 gains. Previous studies have suggested that
perturbations inMCU/MICU1 expression may lead to changes in
oxidativemetabolismandsensitization tocalciumoverload (Csor-
da´s et al., 2013). These data may be particularly relevant to rhab-
domyosarcoma because of the features of muscle differentiation
in this tumor and the role of calcium in muscle contraction.
Recurrent Gene Mutations in Cancer Consensus
Pathways
Combined sequence analyses demonstrated recurrent genetic
lesions (SNVs, indels, and SVs) in eight cancer consensus
genes—NRAS, KRAS, TP53, NF1, RARA, CTNNB1, CARD11,
and PIK3CA—as well as the expected PAX3/7-FOXO1 trans-
locations in ARMS tumors (Figure 6A). One ERMS tumor
(SJRHB026) also had an oncogenic HRAS mutation. All but
one of the cancer consensus gene mutations were found in
ERMS, and 15% (4/27) of ERMS had multiple cancer consensusdiagnostic tumor and the recurrent specimen. Tumor from two different sites
ure 1B. In SJRHB011_D, the labels for gene disrupting SVs have been removed.
ilent mutations have been removed.
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Figure 3. ERMS Clonally Evolve after
Treatment
(A) Heatmap of the 841 SNVs (MAF represented by
the red intensity) used in the analysis of clonal
evolution for SJRHB011. The four distinct clusters
(A–D) are labeled with different colors on the right
side of the heatmap.
(B) Model of clonal evolution of SJRHB011. Clus-
ters of SNVs are displayed as dots in colors
corresponding to those shown in (A).
(C) Heatmap of 1,049 SNVs (MAF represented by
the red color intensity) used in the clonal evolution
analysis of SJRHB012. The six distinct clusters
(A–F) are labeled with different colors on the right
of the heatmap.
(D) Clusters of SNVs are displayed as dots in
colors corresponding to those shown in (A).
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Genomic Analysis of Rhabdomyosarcomagene mutations (Figure 6A). Cancer consensus gene mutations
were validated in 88% (7/8) of the high-risk ERMS tumors,
73% (7/11) of the intermediate-risk tumors, and 20% (2/10) of
the low-risk tumors. The most common cancer consensus
gene mutations were in the RAS pathway (NRAS, KRAS,
HRAS, andNF1) (Figures 6A and 6B and Table 1).Whenwe com-
bined the discovery and validation cohorts, 75% (6/8) of high-
risk ERMS tumors had RAS pathway mutations, 45% (5/11) of
intermediate-risk ERMS tumors had RAS pathway mutations,
and 0% (0/10) of low-risk ERMS tumors had RAS pathway muta-
tions (Table 1); thus, RAS pathway mutations had a significant
association with ERMS risk-group classification (p = 0.00015).
KRAS,HRAS,NRAS, andNF1 gene mutations were rarely found
in combination with other cancer consensus gene mutations,
and they were never found in ARMS.
In our cohort, TP53 gene mutations were accompanied by
FGFR4 mutations (Figures 6A, 6C, and 6D and Table 1). In addi-
tion to TP53genemutations, we also performeddetailed analysis
of CNVs for TP53,MDM2,MDM4, and CDKN2A using the WGS
and SNP 6.0 data, and then we combined those data with716 Cancer Cell 24, 710–724, December 9, 2013 ª2013 Elsevier Inc.RNA-seqdata, p53 IHC, andfluorescence
in situ hybridization (FISH) analysis of all
four loci (Table S7 and Figure S5A). There
were four ERMS samples (SJRHB003,
SJRHB011, SJRHB049, and SJRHB059)
with SNVs in TP53, and all four had
elevated nuclear accumulation of p53
protein (Figure S5B). One ERMS tumor
(SJRHB016) had a homozygous deletion
of TP53 with reduced gene expression
(Table S7). One of the ERMS tumors
(SJRHB012) and one of the ARMS tumors
(SJRHB054) had focalMDM2 gains (>100
copies and 14 copies, respectively) with
increased MDM2 gene expression, and
one of the ERMS tumors (SJRHB020)
had focal homozygous deletion of
CDKN2A with reduced gene expression
(Table S7 and Figure S5). There was one
ERMS sample (SJRHB002) with a gain of
MDM4 (three to five copies in 33% of thecells) (Figure S5C), but there was no increase in gene expression
(Table S7). Overall, by combiningWGS, exome sequencing, SNP
6.0 analysis, transcriptome analysis, p53 IHC, and FISH analysis,
mutations in thep53pathwayweremore common in ERMS (8/31)
than ARMS (1/14). There were no mutations in TP53 or CDKN2A
in our ARMS cohort.
Previous gene expression array analysis of ERMS and ARMS
tumors led to the identification of a 34 metagene expression
signature that is predictive of overall survival for rhabdomyosar-
coma (Davicioni et al., 2010). We used RNA sequence data for 32
tumors from the discovery and validation cohorts to rank the
tumors based on their 34 metagene expression signature (Table
S8). There was no significant association of RAS pathway muta-
tions with 34 metagene rank in our cohort, and a larger study is
required to establish the prognostic significance of RAS pathway
mutations in intermediate-risk ERMS patients.
Targeting Oxidative Stress and RAS Pathways in ERMS
Skeletal muscle cells have unique energymetabolismbecause of
their aerobic capacity and ability to rapidly adapt for short-term
Cancer Cell
Genomic Analysis of Rhabdomyosarcomaanaerobic activity. As a result of their unique metabolic proper-
ties, muscle cells also have a robust antioxidant defense system
to protect the DNA, lipids, and proteins from the deleterious ef-
fects of excess reactive oxygen species (ROS). Cancer cells
also have elevated ROSdue to their increasedmetabolic activity,
oncogenic stimulation (i.e., RAS), andmitochondrial dysfunction.
Therefore, we reasoned that rhabdomyosarcomas may be
particularly susceptible to therapeutics that increase ROS or
that target the cells ability to protect against oxidative stress. In
addition, the association of RAS pathway mutations with ERMS
risk group provided an additional pathway for interventions using
molecularly targeted therapy. To test the efficacy of therapeutics
that target these two pathways, we developed a method to
perform acute short-term cultures with the primary rhabdomyo-
sarcoma orthotopic xenografts described above. In brief, the
tumor cells in matrigel were injected into the flank muscle of
immunocompromised mice. Several weeks later when the tumor
masses were palpable, they were isolated and dispersed into a
single-cell suspension (Figures 7A–7C). The cells can be grown
for up to 96 hr inmuscle differentiationmedium in 384-well dishes
with reproducible survival and growth kinetics. Next, we devel-
oped a custom compound library with 207 compounds including
Food and Drug Administration-approved drugs, molecules in
clinical development, and well-characterized small molecules
with biological activity (Table S9). The library included chemo-
therapeutics used to treat pediatric cancer, agents that perturb
the oxidative stress pathway, and molecules that target the
RAS pathway. The library was screened in dose response in trip-
licate against each of the six xenografts and several rhabdomyo-
sarcoma cell lines (Table S9). As a positive control, we used
staurosporine and as a negative control we used DMSO at the
same concentration in the drug-treated wells. There was robust
separation between the positive and negative controls, and the
mean z’ value was between 0.48 and 0.81 across the experi-
ments (Table S10 and Figures S6A and S6B). Overall,
the xenografts were less sensitive to the agents in the targeted
library than the cell lines (Figure 7D). None of the drugs that target
the RAS pathway had significant activity against the xenografts,
including the tumor that had anNRASmutation (SJRHB013). We
also included molecules that target the phosphatidylinositol
3-kinase (PI3K) pathway because of the interplay between the
RAS and PI3K pathways (Gysin et al., 2011). None of these
agents had significant activity except for the dual PI3K and
mammalian target of rapamycin inhibitor BGT-226 (Figures 7D
and 7E). There are now several clinical trials testing the combina-
tion of PI3K inhibitors and RAS pathway inhibitors, so we tested
the combination of BGT-226 with all of the drugs in our library.
Even these combinations failed to show significant increase in
cytotoxicity for our ERMS xenografts (Table S9). These data
are consistent with phosphoprotein analysis for the RAS and
PI3K pathways (Figures S6C and S6D) showing little, if any,
deregulation of those pathways in our xenografts.
In contrast to compounds targeting RAS and PI3K pathways,
the agents that targeted oxidative stress were more active.
The histone deacetylase (HDAC) inhibitors were active as a
class with panobinostat showing the most activity (Figures 7D
and 7E). In addition, carfilzomib, auranofin, cerivastatin, alvoci-
dib, and ouabain showed significant activity against the ERMS
xenografts. Each of these drugs can increase oxidative stress,Caand several have been shown to be synergistic by targeting
oxidative stress and inducing mitochondrial cell death (dis-
cussed below). Taken together, these data suggest that drugs
that increase oxidative stress and ROS production in ERMS cells
may be effective for the treatment of diagnostic and recurrent
ERMS tumors.
DISCUSSION
Genetic Landscape of Rhabdomyosarcoma
It has been previously shown that chromosome 8 was gained in
74% of ERMS tumors (Williamson et al., 2010). We identified
chromosome 8 gains in 92% (11/12) of the ERMS tumors, and
we found that two genes on chromosome 10 that control calcium
uptake in mitochondria (MCU andMICU1) are downregulated in
the tumors with chromosome 8 gain. This may indicate that there
is a negative regulator ofMCU andMICU1 on chromosome 8. In
a separate aCGH study of 26 ERMS tumors, CDKN2A-homozy-
gous deletions were found in 23% (6/26) of tumors, and hetero-
zygous deletion through loss of chromosome 9p was found in
most of the remaining tumors (Paulson et al., 2011). In our cohort,
we identified one ERMS tumor showing CDKN2A-homozygous
loss (8%) and one other ERMS tumor showing a heterozygous
deletion. We did not find any CDKN2A mutations in ARMS tu-
mors. We also analyzed the other key genes in the p53 pathway,
including TP53,MDM4, andMDM2. In total, mutations in the p53
pathway were identified in 19% of the ERMS tumors (6/31) and
7% (1/14) of ARMS tumors. This difference between the two
studies may be due, in part, to the larger number of low-risk
ERMS tumors in our study.
Paulson et al. (2011) also reported patterns of activation of the
RAS pathway by oncogenic mutation in HRAS, KRAS, or NRAS
(42% [12/26]) or by homozygous deletions of NF1 (15% [4/26]).
These data are consistent with those from three other studies
showing RAS pathwaymutations in 35% (5/14), 22% (7/31) (Mar-
tinelli et al., 2009; Stratton et al., 1989), and 11.7% (Shukla et al.,
2012) of ERMS tumors. In our study, 58% (11/19) of the high-risk
and intermediate-risk ERMS tumors had RAS pathway muta-
tions, and RAS pathway mutations were significantly associated
with risk-group assignment (p = 0.0015). None of the ARMS
tumors in our discovery or validation cohorts (17 specimens)
had RAS pathway mutations or TP53/FGFR4 gene mutations.
A much larger cohort of ERMS tumors is needed to determine
the incidence and significance of RAS pathway mutations with
respect to overall survival.
The only cancer consensus gene that was mutated in our
ARMS cohort was PIKC3A in one sample (SJRHB008). There
was also one ERMS tumor with a PIKC3Amutation (SJRHB057).
One of the mutations, H1047R, is a hotspot mutation and the
other, N345K, is a raremutation that has been shown to be onco-
genic in cell culture (Gymnopoulos et al., 2007). These data sug-
gest that multiple cancer consensus pathways are mutated in
ERMS and the PAX3/7-FOXO1 translocation is the major onco-
genic driver in ARMS.
In a previous study comparing genetically engineered mouse
models of rhabdomyosarcoma to primary human tumors,
Keller and colleagues analyzed the p53, SHH, RB, and
RAS pathways by comparing their gene expression signatures
(Rubin et al., 2011). They concluded that fusion-negativencer Cell 24, 710–724, December 9, 2013 ª2013 Elsevier Inc. 717
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Figure 4. Orthotopic Xenografts Retain Molecular and Cellular Features of the Patient’s Tumor
(A) Representative H&E and myogenin IHC from a primary tumor (SJRHB012_D) and the corresponding xenograft (SJRHB012_X).
(B) Transmission electron micrographs of SJRHB012_X showing features of rhabdomyosarcoma, including myofibers and glycogen. Nuclei (n) are indicated.
(C) CIRCOS plot of exonic SNVs for the SJRHB012_D/SJRHB012_X pair. Gene names in black contain SNVs found in the primary and xenograft samples, and
gene names shown in blue are unique to the xenograft.
(D) SNP 6.0 analysis of copy number changes (left) and LOH (right) for the matched primary and xenograft samples, with red showing gain and blue showing loss
for copy number and blue showing LOH for the lower panel.
(legend continued on next page)
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Figure 5. ERMS Have WNT Mutations
(A) Activating mutations in the b-catenin gene in
SJRHB004 and SJRHB005 in the discovery
cohort.
(B) IHC of b-catenin for SJRHB004, SJRHB005,
and an alveolar rhabdomyosarcoma (SJRHB008).
See also Figure S4 and Tables S3, S4, S5, and S6.
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Genomic Analysis of Rhabdomyosarcomarhabdomyosarcomas (ERMS) with a RAS signature always had
perturbations in at least one other pathway (SHH, RB, or p53).
No other genetic or histologic data were presented in that study
to confirm the findings. This is important because signaling
through these pathways is complex and using a metagene
approach may not accurately identify pathway perturbations.
This is particularly true for the RAS pathway that is regulated pri-
marily at the level of protein phosphorylation rather than gene
expression.
In our characterization of the genomic landscape of rhabdo-
myosarcoma, we did not find significant overlap of mutations
in the p53, SHH, RB, and RAS pathways. However, we cannot
rule out the possibility of nongenetic factors contributing to
pathway perturbations, and more comprehensive integration of
genetic and epigenetic profiles will help to resolve this discrep-
ancy. Indeed, our data suggest that several genes that regulate
the RAS pathway or similar receptor tyrosine kinase pathways
are differentially methylated in rhabdomyosarcomas, including
THEM4, DAB2, KSR1, ELMO1, SH3D19, NCK2, and JAK1.
Developmental Pathways in Rhabdomyosarcoma
Rhabdomyosarcomas express multiple genes and pathways
characteristic of muscle cell differentiation, and electron micro-
scopy analysis of ERMS and ARMS tumors has demonstrated
that tumor cells have features of skeletal muscle, including myo-
fibers (Skalli et al., 1988). Our analysis of previously published
gene expression array data revealed that expression of genes
in the SHH and WNT pathways differs significantly between
ERMS and ARMS tumors, and our RNA-seq and DNA methyl-
ation analyses provided additional validation. No mutations in
the SHH pathway were found in our cohort, but we identified
b-catenin-activating mutations in 7% (2/29) of ERMS tumors
and nuclear accumulation of b-catenin in 20% of ERMS(E) Correlation analysis of the RNA-seq data for a representative primary tumor and xenograft pair with a
fragments per kilobase of transcript per million.
(F) Heatmap of DNA methylation analysis for the matched diagnostic and xenograft pairs.
See also Figure S3.
Cancer Cell 24, 710–724,tumors (6/30). Shukla et al. (2012) identi-
fied CTNNB1 mutations in 2/60 ERMS
tumors, but there was no validation
of nuclear accumulation of b-catenin.
The nuclear accumulation of b-catenin
was heterogeneous and in tumor
sample SJRHB004, the b-catenin-acti-
vating mutation was in a minor clone; in
SJRHB005, it was present in the major
clone. There was no evidence of activa-
tion of WNT signaling in ARMS tumors in
our cohort. Previous studies in micehave shown that b-catenin plays an important developmental
stage-specific role in muscle cell development and that activa-
tion of b-catenin can lead to ectopic proliferation (Hutcheson
et al., 2009). Activation of b-catenin is not sufficient to induce
tumorigenesis of muscle progenitors or differentiation of muscle
cells in mice, but in combination with other mutations, it may
contribute to tumorigenesis in human rhabdomyosarcoma.
Indeed, in our cohort, b-catenin-activating mutations were found
in combination with LRP1B mutations.
Beyond SHH and WNT signaling, we identified 101 muscle-
enriched genes mutated in rhabdomyosarcoma. Among those
101 genes, only eight genes were recurrently mutated in at least
two tumor samples, and one gene, TTN, was recurrently mutated
in three samples. The TTN gene is one of the largest genes in the
genome, and it is mutated in most pediatric solid tumors; thus, it
is difficult to assess the functional significance of TTN mutations
in rhabdomyosarcoma. A much larger study is required to eluci-
date the significance of mutations in genes implicated in muscle
development or differentiation. Our DNA methylation data also
provided additional insight into muscle developmental pathways
that may be deregulated in rhabdomyosarcoma, including LBX1,
FOXK1,ZFHX3,MEF2D,HOXD3,ZFP42,DLK2,MYF5, andFHL3.
Intratumor Heterogeneity and Clonal Evolution of
Rhabdomyosarcoma
We identified significant intratumor heterogeneity in 10/15 of the
tumors, and two of them had multiple clones. Interestingly, three
of the tumors had a founding clone with relatively few SNVs, and
the majority of SNVs in the tumor were present in a clone that
grew out of that clone. There was no difference between
ARMS and ERMS tumors with respect to tumor heterogeneity.
We included two patients in our discovery cohort that had
diagnostic and recurrent tumors to begin to explore the clonalcoefficient of 0.752 for this pair (red line). FPMK,
December 9, 2013 ª2013 Elsevier Inc. 719
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Figure 6. The RAS and p53 Pathways Are Recurrently Mutated in ERMS
(A) Summary of mutations in cancer consensus genes and recurrent mutations in noncancer consensus genes in the discovery (bold) and validation cohorts.
Tumor samples are organized by histologic subtype and stage.
(B) Distribution of oncogenic mutations in NRAS, KRAS, and HRAS.
(C and D) Distribution of missense mutations in FGFR4 (C) and TP53 (D).
See also Figure S5 and Tables S7 and S8.
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Table 1. RAS, NF1, TP53, and FGFR4 Mutations in ERMS
Sample Risk Groupa NRAS KRAS HRAS NF1 TP53 FGFR4
SJRHB013 I Q61K/WT
SJRHB027 H Q61K/WT
SJRHB028 H Q61K/WT
SJRHB056 H G12A/WT
SJRHB057 I Q61K/WT
SJRHB023 I G12C/WT
SJRHB045 I G12A/WT
SJRHB026 H G13R/WT
SJRHB047 H C1939_N1942fs/WT
SJRHB039 I L1855I/WT
SJRHB049 H W784Cb A276Db V550Lb
SJRHB011 I C176F/D N535K/WT
SJRHB059 H P250L+ L308Vc G528C+ V550Ld
aI, intermediate risk; H, high risk.
bData from exome capture. The wild-type allele was not present, possibly reflecting deletion or copy neutral LOH.
cData from exome capture. There were relatively few reads for the corresponding wild-type nucleotide, suggesting deletion or copy neutral LOH.
dData from exome capture. There were relatively few reads for the corresponding wild-type nucleotide, suggesting deletion or copy neutral LOH.
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particular interest because the overall survival for patients with
recurrent rhabdomyosarcoma is less than 30%, and nothing is
known about how the tumors evolve in the context of current
standard of care therapy. Our analysis suggests that chemo-
therapy can eliminate the major clone in a diagnostic tumor,
and a minor subclone can then seed the recurrent tumor after
therapy and continue to acquire mutations. Thus, not only are
the two ERMS tumors in our analysis complex with respect to tu-
mor heterogeneity at diagnosis but also they are significantly
different at the time of recurrence and at individual recurrent
sites. These data highlight the importance of performing
comprehensive genomic analyses of diagnostic and recurrent
tissue specimens from multiple sites for rhabdomyosarcoma to
identify the genetic lesions that contribute to progression and
resistance to therapy and to more effectively identify therapeutic
approaches for those recurrent rhabdomyosarcoma patients. As
more targeted agents become available, biopsy of the recurrent
tumor may become an important intervention for selection of
therapy since the mutations present at recurrence may differ
from those present at initial diagnosis.
Implications for Preclinical Models of ERMS and ARMS
To model ARMS in the mouse, Keller et al. (2004) generated a
conditional Pax3-Foxo1 knockin mouse line that could be
induced to express the Pax3-Foxo1 fusion protein with cell-
type-specific Cre expression. However, expression of the fusion
protein was not sufficient to promote ARMS formation, and only
when combined with conditional inactivation of Trp53 or Cdkn2a
did the mice develop ARMS. In our study, none of the ARMS tu-
mors had TP53 orCDKN2Amutations. Indeed, only one of the 14
ARMS samples in our cohort had a lesion in the p53 pathway
(MDM2 amplification). It is not knownwhether this species differ-
ence reflects a divergence in the cellular origins of the tumor,
differences in the epigenetic landscape of the cell of origin for
ARMS across species, or some other cell autonomous or non-
cell-autonomous difference that affects tumor initiation or pro-Cagression. Our data suggest that conditional activation of the
RAS pathway will prove useful for modeling intermediate- or
high-risk ERMS in the mouse and that inactivation of the Trp53
gene in combination with an activating mutation in Fgfr4 may
provide another model of intermediate- or high-risk ERMS.
Targeting the Oxidative Stress Pathway in ERMS
Skeletal muscle cells and cancer cells have high levels of ROS
because of their unique metabolic demands. Therefore, we
reasoned that a cancer with features of skeletal muscle (rhabdo-
myosarcoma) may have even higher levels of ROS than other
cancer cells and be particularly sensitive to therapeutics that in-
crease oxidative stress. Indeed, one of themost active agents for
the treatment of rhabdomyosarcoma, actinomycin-D, increases
oxidative stress (Minai et al., 2013; Tsuruga et al., 2003). The
genomic data presented here suggest that ERMS tumors have
elevated ROS because they have higher rates of G/T transver-
sions and some increase in expression of genes in the p38MAPK
pathway (Wagner and Nebreda, 2009). Also, the majority of
ERMS tumors have chromosome 8 gains (92% in our cohort)
and show deregulation of MCU/MICU1 expression that, in turn,
can lead to mitochondrial dysfunction and oxidative stress
(Block and Gorin, 2012). Several genes implicated in regulation
of metabolism, mitochondrial function, and oxidative stress
were differentially methylated in rhabdomyosarcomas, including
PTK2, COX7A1, NOSIP, NOS1, ATP2A3, DDAH1, GLRX, and
TXNDC12. In our study, the ERMS xenografts are sensitive to
the thioredoxin reductase inhibitor auranofin (Liu et al., 2012).
The thioredoxin pathway is regulated by epigenetic processes
controlled in part by HDACs, and one of the cytotoxic mecha-
nisms of HDAC inhibitors is perturbations in the expression of
the thioredoxin pathway (Butler et al., 2002). Our data on the ac-
tivity of HDAC inhibitors for the ERMS xenografts are consistent
with this mechanism of action and the susceptibility of the oxida-
tive stress pathway in these tumors. Two other drugs that show
activity against the ERMS xenografts, carfilzomib and alvocidib,
act synergistically with HDAC inhibitors by targetingncer Cell 24, 710–724, December 9, 2013 ª2013 Elsevier Inc. 721
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Figure 7. ERMS Xenografts Are Sensitive to Drugs that Target Oxidative Stress
(A) Pictures of orthotopic xenograft of SJRHB012_X in the muscle of NSG immunocompromised mice.
(B) Tumors isolated from the corresponding mice shown in (A).
(C) Differential interference contrast micrograph of primary SJRHB012_X cells in a 384-well dish for drug screening. Scale bar represents 10 mm.
(D)Heatmapandunsupervisedclusteringof drugsensitivity for two rhabdomyosarcomacell lines,RDandRMS13, and thesix xenografts characterized in this study.
(E) Dose-response curves of cell lines and xenografts to some of the compounds investigated. CPM, cyclophosphamide; HDACi, histone deacetylase inhibitors;
VCR, vincristine; DACT, actinomycin-D; DOXO, doxorubicin.
See also Figure S6 and Tables S9 and S10.
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cells (Dasmahapatra et al., 2006, 2010, 2011; Huang et al., 2010).
Indeed, one of the major mechanisms of action of the HDAC in-
hibitors is through changes in expression of thethoredoxin reduc-
tase pathway, and our data on HDAC inhibitors as a class are
consistent with this hypothesis. Cervistatin is a synthetic statin
used to lower cholesterol and prevent cardiovascular disease.
In cardiac myocytes, it is believed that statins reduce oxidative
stress. However, it has been shown that this effect is cell-type
specific and in skeletal muscle, statins can have the opposite ef-
fect and increase oxidative stress contributing to rhabdomyoly-
sis, amajor side effect of statins (Bouitbir et al., 2012). Cervistatin
waswithdrawn from themarket due to the high rate of deaths and
other side effects related to rhabdomyolysis. Finally, ouabain is a
Na+/K+ ATPase inhibitor that can have pleiotropic effects in cells.
In myocytes, ouabain can lead to opening of ATP-sensitive mito-
chondrial potassium channels and concomitant increase in ROS
(Tian et al., 2003). Taken together, these genomic,molecular, and
cellular data suggest that therapeutics that increase reactive
oxygen in rhabdomyosarcoma may be particularly effective
and may contribute synergistically to current standard of care
using vincristine, actinomycin, and cyclophosphamide. The syn-
ergistic effects of carfilzomib or alvocidib with HDAC inhibitors is
particularly promising.
EXPERIMENTAL PROCEDURES
Full details of sample acquisition, molecular and biochemical procedures,
informatics, and WGS are provided in the Supplemental Information. Forty-
eight of the tumors in this study were from St. Jude Children’s Research Hos-
pital (SJCRH) patients, and five were obtained from the Nationwide Children’s
Hospital Biopathology Center. The SJCRH Institutional Review Board
approved experiments involving human subjects, and informed consent was
obtained from all subjects. The SJCRH Institutional Animal Care and Use
Committee approved all experiments involving animals.
Rhabdomyosarcoma Xenografts
Excess, deidentified tumor material was collected from patients with rhabdo-
myosarcoma at SJCRH in agreement with local institutional ethical regulations
and institutional review board approval. Tumor tissue was initially implanted in
the flank location of NOD scid gamma (NSG) mice. After sufficient tumor
growth, orthotopic xenografts were created by processing the flank tumor tis-
sue into a single-cell suspension by enzymatic dissociation and injection into
the hind leg muscle of CD-1 nude mice. Tumor growth was monitored by
manual palpation. After tumor development, the tumor was harvested and pro-
cessed using the same dissociation technique that was use to isolate cells for
drug screening.
Orthotopic Xenograft Intramuscular Injection
Rhabdomyosarcoma cells were suspended in matrigel (BDWorldwide catalog
no. 354234) at a concentration of 13 104 cells/ml and placed on ice. Recipient
CD-1 nude mice were manually restrained and injected with 100 ml of cell sus-
pension intramuscularly into the lateral thigh region of the hind leg.
Rhabdomyosarcoma Tumor Dissociation
Rhabdomyosarcoma tumor tissue was harvested from CD-1 nude orthotopic
xenografts. The tumor was placed through a tumor press and then rinsed
with Dulbecco’s modified Eagle’s medium (DMEM) (Lonza catalog no. 12-
604F). The tumor suspension was transferred to a 50-ml-conical tube and filled
with DMEM. Dissociation was done by adding 600 ml of trypsin (10 mg/ml;
Sigma catalog no. T9935) and 50 mg of type II collagenase (275 U/mg; Wor-
thington Biochemical catalog no. 4177), and then the tube was placed in a
37Cwater bath for 10min. Dissociation was stopped by adding 600 ml of soy-
bean trypsin inhibitor (10mg/ml; Sigmacatalog no. T6522). Deoxyribonuclease
I (2 mg/ml; Sigma catalog no. D4513) and magnesium chloride (1 M) were
added in equal amounts in 60 ml increments until tumor fragments easily settledCaat the bottom of the tube. The tumor suspension was filtered with a 40 mm cell
strainer and centrifuged at 4503 g (g = relative centrifugal force) for 5 min. The
supernatant was discarded, and 10 ml of red blood cell lysis solution (5 PRIME
catalog no. 2301310) was added and allowed to incubate at room temperature
for 10min. A solution of PBSwithout calciumormagnesium (PBS-minus; Lonza
catalog no. 17-516F)/10% fetal bovine serum (FBS) (Biowest catalog no.
SO1520) was added to fill a 50-ml-conical tube, and the cell suspension was
centrifuged at 450 3 g for 5 min. The supernatant was discarded, and the
cell pellet was resuspended in PBS-minus/10% FBS for counting.
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